Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Waschbisch, Anne ^a   Sanderson, Nicholas ^b   Krumbholz, Markus ^c   Vlad, George ^d   Theil, Diethilde ^c,e   Schwab, Stefan ^a   Mäurer, Mathias ^a,f   Derfuss, Tobias ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NewYork Presbyterian Hospital   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f CARITAS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CD14 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; DIHYDROXYCOLECALCIFEROL; IMMUNOGLOBULIN LIKE TRANSCRIPT 3; IMMUNOGLOBULIN LIKE TRANSCRIPT 4; INTERFERON BETA SERINE; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; RECEPTOR; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; DIHYDROXY-VITAMIN D3; IMMUNOGLOBULIN RECEPTOR; LILRB2 PROTEIN, HUMAN; LILRB4 PROTEIN, HUMAN; MEMBRANE PROTEIN; VITAMIN D;

ANTIGEN PRESENTING CELL; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; MONOCYTE; MONOTHERAPY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIGEN-PRESENTING CELLS; B7 ANTIGENS; DRUG SYNERGISM; HUMANS; INTERFERON-BETA; MEMBRANE GLYCOPROTEINS; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; UP-REGULATION; VITAMIN D;

EID: 84920491105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115488     Document Type: Article

References (31)

1. Lu HK, Rentero C, Raftery MJ, Borges L, Bryant K, et al. (2009) Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases. J Biol Chem 284: 34839-34848.
2. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, et al. (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185: 1743-1751.
3. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, et al. (2002) Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3: 237-243.
4. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, et al. (2003) High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11: 245-258.
5. Chang CC, Liu Z, Vlad G, Qin H, Qiao X, et al. (2009) Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol 182: 5208-5216.
6. Vlad G, Chang CC, Colovai AI, Vasilescu ER, Cortesini R, et al. (2010) Membrane and soluble ILT3 are critical to the generation of T suppressor cells and induction of immunological tolerance. Int Rev Immunol 29: 119-132.
7. Vlad G, Suciu-Foca N (2012) Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3. Exp Mol Pathol 93: 294-301.
8. Korn T (2008) Pathophysiology of multiple sclerosis. J Neurol 255 Suppl 6: 2-6.
9. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198: 71-78.
10. Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, et al. (2001) The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2: 605-611.
11. Joller N, Peters A, Anderson AC, Kuchroo VK (2012) Immune checkpoints in central nervous system autoimmunity. Immunol Rev 248: 122-139.
12. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, et al. (2007) Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 178: 7432-7441.
13. Vlad G, D'Agati VD, Zhang QY, Liu Z, Ho EK, et al. (2008) Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice. Diabetes 57: 1878-1886.
14. Vlad G, Suciu-Foca N (2013) Tolerogenic dendritic cells and induction of Tsuppressor cells in transplant recipients. Methods Mol Biol 1034: 359-371.
15. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, et al. (2004) Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous Tcell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 155: 172-182.
16. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, et al. (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25- dihydroxyvitamin D3. Blood 106: 3490-3497.
17. Ortler S, Leder C, Mittelbronn M, Zozulya AL, Knolle PA, et al. (2008) B7-H1 restricts neuroantigenspecific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol 38: 1734-1744.
18. Mueller DL (2010) Mechanisms maintaining peripheral tolerance. Nat Immunol 11: 21-27.
19. Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27: 591-619.
20. Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG (2010) Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler 16: 30-38.
21. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmuller H, et al. (2003) Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 17: 1892-1894.
22. Ascherio A, Munger KL, Simon KC (2010) Vitamin D and multiple sclerosis. Lancet Neurol 9: 599-612.
23. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79: 261-266.
24. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, et al. (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68: 193-203.
25. Ascherio A, Munger KL, White R, Kochert K, Simon KC, et al. (2014) Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurol.
26. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, et al. (2013) The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 19: 1571-1579.
27. Stewart N, Simpson S Jr, van der Mei I, Ponsonby AL, Blizzard L, et al. (2012) Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 79: 254-260.
28. Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, et al. (2006) Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol 176: 2790-2798.
29. Gleissner CA, Zastrow A, Klingenberg R, Kluger MS, Konstandin M, et al. (2007) IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Eur J Immunol 37: 177-192.
30. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
31. Lassmann H, Raine CS, Antel J, Prineas JW (1998) Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86: 213-217.